NIH/Nat. Inst. of General Medical Sciences – 2P20GM109005
“Center for Studies on Host Response to Cancer Therapy”
08/17/20 – 05/31/25
Boyle EM, Deshpande S, Tytarenko R, [et al., including Bauer MA]. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nature communications. 2021 12(1):293. PMID: 33436579.
Danziger SA, McConnell M, Gockley J, [et al., including Bauer M]. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. PLoS medicine. 2020 17(11):e1003323. PMID: 33147277. PMCID: PMC7641353.
Choudhury SR, Ashby C, Tytarenko R, [et al., including Bauer M]. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. Journal of hematology & oncology. 2020 13(1):108. PMID: 32762714. PMCID: PMC7409490.
Ashby C, Rutherford M, Bauer MA, [et al.]. TarPan: an easily adaptable targeted sequencing panel viewer for research and clinical use. BMC bioinformatics. 2020 21(1):144. PMID: 32293247. PMCID: PMC7158102.
Bauer MA, Ashby C, Wardell C, [et al.]. Differential RNA splicing as a potentially important driver mechanism in multiple myeloma. Haematologica. 2020. PMID: 32079689.
Boyle EM, Ashby C, Tytarenko R, [et al., including Bauer MA]. BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020. PMID: 31988198.
Kiffer F, Alexander T, Anderson J, [et al., including Bauer M]. Late Effects of 1H + 16O on Short-Term and Object Memory, Hippocampal Dendritic Morphology and Mutagenesis. Frontiers in behavioral neuroscience. 2020 14:96. PMID: 32670032. PMCID: PMC7332779.
Rasche L, Alapat D, Kumar M, [et al., including Bauer M]. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia. 2019 33(7):1713-1722. PMID: 30573775. PMCID: PMC6586541.
Mikulasova A, Ashby C, Tytarenko RG, [et al., including Bauer MA]. Microhomology-mediated end joining drives complex rearrangements and over expression of MYC and PVT1 in multiple myeloma. Haematologica. 2019. PMID: 31221783.
Ashby C, Tytarenko RG, Wang Y, [et al., including Bauer M]. Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53. Oncotarget. 2019 10(7):732-737. PMID: 30774775. PMCID: PMC6366829.
Ashby C, Peterson EA, Bauer M, Johann DJ. A Scalable and Adaptive Approach for NGS Analyses Leveraging High-Performance Computing. Pathological Specimens and Genomics Medicine: Emerging Issues. 2019:248.
Walker BA, Mavrommatis K, Wardell CP, [et al., including Bauer M]. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019 33(1):159-170. PMID: 29967379. PMCID: PMC6326953.
Boyle EM, Ashby C, Wardell CP, [et al., including Bauer MA]. The genomic landscape of plasma cells in systemic light chain amyloidosis. Blood. 2018 132(26):2775-2777. PMID: 30446495.
Morgan GJ, He J, Tytarenko R, [et al., including Bauer M]. Kinase domain activation through gene rearrangement in multiple myeloma. Leukemia. 2018 32(11):2435-2444. PMID: 29654269. PMCID: PMC6224403.
Walker BA, Mavrommatis K, Wardell CP, [et al., including Bauer M]. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018 132(6):587-597. PMID: 29884741. PMCID: PMC6097138.
Thanendrarajan S, Tian E, Qu P, [et al., including Bauer M]. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. 2017 102(9):e364-e367. PMID: 28550191. PMCID: PMC5685226.
Rasche L, Chavan SS, Stephens OW, [et al., including Bauer M]. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nature communications. 2017 8(1):268. PMID: 28814763. PMCID: PMC5559527.
Chavan SS, He J, Tytarenko R, [et al., including Bauer M]. Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Blood cancer journal. 2017 7(2):e535. PMID: 28234347. PMCID: PMC5386330.
Weinhold N, Ashby C, Rasche L, [et al., including Bauer MA]. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016 128(13):1735-44. PMID: 27516441. PMCID: PMC5043128.
Peterson EA, Bauer M, Chavan SS, [et al.]. Enhancing Cancer Clonality Analyses with Integrative Genomics. BMC Bioinformatics. 2015 25(16 Suppl 13):S1.
Bauer MA, Berleant D, Cornell AP, Belford RE. WikiHyperGlossary (WHG): an information literacy technology for chemistry documents. Journal of cheminformatics. 2015 7:22. PMID: 26110024. PMCID: PMC4477724.